Further evidence for H-2-unrestricted induction of minor histocompatibility antigens-specific T cell immunity in vivo.
Antigenic requirements for inducing minor histocompatibility antigens (MIHA)-specific T cell immunity for second set rejection (SSR) of a MIHA-allogeneic tumor were studied. An intravenous injection of surprisingly small numbers (10(4)-10(5] of live allogenetic spleen cells (SC) effectively primed mice for SSR of the allogeneic tumor, and this immunity was developed as early as 2-3 days after injection of the SC. In contrast, sonication-disrupted allogeneic SC, which should be readily processed by host antigen presenting cells (APC), were not active as immunogens, even at a dose 1000 times higher than the minimum effective dose of live SC. The possibility that host APC preferentially receive MIHA antigens shed by live allogeneic SC for T cell activation was ruled out. These results demonstrated that antigen processing via conventional pathways is very little involved in the mechanism of T cell activation. Under such restricted experimental conditions, the induction phase but not the effector phase of the MIHA-specific T cell immunity was shown to be H-2-unrestricted.
Mizoguchi
K
K
Department of Immunology, Nagoya University School of Medicine, Japan.
Isobe
K
K
Yoshida
T
T
Iwamoto
T
T
Hasegawa
T
T
Ding
L
L
Rahman
S M
SM
Miyata
T
T
Nagase
F
F
Shimokata
K
K
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D006084:Graft Rejection; D006183:H-2 Antigens / Q000276:immunology*; D006649:Histocompatibility Antigens / Q000276:immunology*; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology; D013154:Spleen / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D006183:H-2 Antigens; D006649:Histocompatibility Antigens